About Index Trending news
Lists
Pricing
CureVac AG

CureVac AG

CureVac AG

Founded in 2000 as a spinoff from the University of Tbingen in Germany, CureVac is a technology leader in the development of drugs that are based on the molecule Messenger RNA (mRNA).

Elsewhere

Featured on

Alexa global traffic share

Latest funding
Venture capital (Series G)
$29,500,000
Landeskreditbank Baden-Württemberg, LBBW Asset Management, Baden-Württembergische Versorgungsanstalt für Ärzte
Employees

Team size

200+
Locations
HQ
Headquarters
$29,500,000 Venture capital (Series G)
ENDPOINTS NEWS

CureVac grabs a $29.5M round to fuel its mRNA development efforts

Funding